EndoPredict® Extended Endocrine Trial (EXET)
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Primary Invasive Breast Cancer
Interventions: OTHER: Observational
Sponsor: Myriad Genetic Laboratories, Inc.